Growth Metrics

Lineage Cell Therapeutics (LCTX) Tax Provisions (2019 - 2023)

Lineage Cell Therapeutics has reported Tax Provisions over the past 4 years, most recently at -$1.8 million for Q1 2023.

  • For Q1 2023, Tax Provisions changed N/A year-over-year to -$1.8 million; the TTM value through Dec 2023 reached -$1.8 million, up 87.14%, while the annual FY2025 figure was -$5.3 million, N/A changed from the prior year.
  • Tax Provisions for Q1 2023 was -$1.8 million at Lineage Cell Therapeutics, down from -$1.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $4.4 million in Q1 2019 and troughed at -$14.0 million in Q4 2019.
  • A 3-year average of -$1.7 million and a median of -$6000.0 in 2019 define the central range for Tax Provisions.